Across TCGA pan-cancer cohorts, CCL1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CCL1 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher CCL1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCL1 expression acts as an unfavorable survival marker.
COAD and BLCA are the cancer types where CCL1 Mutation most reproducibly stratifies survival.